• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

细胞周期、发育及癌症中的关键因子：细胞周期蛋白依赖性激酶4（CDK4）

CDK4: A Key Player in the Cell Cycle, Development, and Cancer.

作者信息

Baker Stacey J, Reddy E Premkumar

机构信息

Mount Sinai School of Medicine, New York, NY, USA.

出版信息

Genes Cancer. 2012 Nov;3(11-12):658-69. doi: 10.1177/1947601913478972.

DOI:10.1177/1947601913478972
PMID:23634254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3636745/
Abstract

The cell cycle is regulated in part by cyclins and their associated serine/threonine cyclin-dependent kinases, or CDKs. CDK4, in conjunction with the D-type cyclins, mediates progression through the G1 phase when the cell prepares to initiate DNA synthesis. Although CDK4-null mutant mice are viable and cell proliferation is not significantly affected in vitro due to compensatory roles played by other CDKs, this gene plays a key role in mammalian development and cancer. This review discusses the role that CDK4 plays in cell cycle control, normal development, and tumorigenesis as well as how small molecule inhibitors of CDK4 can be used to treat disease.

摘要

细胞周期部分受细胞周期蛋白及其相关的丝氨酸/苏氨酸细胞周期蛋白依赖性激酶（即CDK）调控。CDK4与D型细胞周期蛋白共同作用，在细胞准备启动DNA合成时介导细胞通过G1期。尽管CDK4基因敲除的突变小鼠能够存活，且由于其他CDK发挥的补偿作用，细胞增殖在体外未受到显著影响，但该基因在哺乳动物发育和癌症中起着关键作用。本文综述了CDK4在细胞周期调控、正常发育和肿瘤发生中的作用，以及CDK4小分子抑制剂如何用于治疗疾病。

相似文献

1
CDK4: A Key Player in the Cell Cycle, Development, and Cancer.细胞周期、发育及癌症中的关键因子：细胞周期蛋白依赖性激酶4（CDK4）
Genes Cancer. 2012 Nov;3(11-12):658-69. doi: 10.1177/1947601913478972.
2
CDK4: a master regulator of the cell cycle and its role in cancer.细胞周期蛋白依赖性激酶4（CDK4）：细胞周期的主要调节因子及其在癌症中的作用。
Genes Cancer. 2022 Aug 25;13:21-45. doi: 10.18632/genesandcancer.221. eCollection 2022.
3
B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors.B细胞抗原受体介导的细胞周期蛋白依赖性视网膜母细胞瘤蛋白激酶激活及与Fcγ受体共交联的抑制作用。
J Immunol. 1999 Sep 15;163(6):3160-8.
4
[Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].[控制细胞周期的分子机制：基础方面及其对肿瘤学的意义]
Cancer Radiother. 2001 Apr;5(2):109-29. doi: 10.1016/s1278-3218(01)00087-7.
5
Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells.在人乳腺上皮细胞中，细胞周期蛋白D2优先激活细胞周期蛋白依赖性激酶2而非细胞周期蛋白依赖性激酶4。
Oncogene. 1997 Mar 20;14(11):1329-40. doi: 10.1038/sj.onc.1200951.
6
Temporal patterns of gene expression of G1-S cyclins and cdks during the first and second mitotic cell cycles in mouse embryos.小鼠胚胎第一次和第二次有丝分裂细胞周期期间G1-S期细胞周期蛋白和细胞周期蛋白依赖性激酶基因表达的时间模式。
Mol Reprod Dev. 1996 Nov;45(3):264-75. doi: 10.1002/(SICI)1098-2795(199611)45:3<264::AID-MRD2>3.0.CO;2-Q.
7
Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.D1型、D3型、E型和A型细胞周期蛋白 - 细胞周期蛋白依赖性激酶复合物对T - 47D人乳腺癌细胞底物的差异磷酸化作用。
J Biol Chem. 1997 Dec 26;272(52):33327-37. doi: 10.1074/jbc.272.52.33327.
8
Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes.大鼠肝脏再生过程中cdk4和cdk2的激活与细胞周期蛋白-cdk复合物的核内重排有关。
Hepatology. 1999 Feb;29(2):385-95. doi: 10.1002/hep.510290226.
9
Control of G1 progression by D-type cyclins: key event for cell proliferation.D型细胞周期蛋白对G1期进程的调控：细胞增殖的关键事件。
Leukemia. 1997 Apr;11 Suppl 3:347-51.
10
Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.终末红细胞分化过程中的细胞周期退出与p27（Kip1）的积累和cdk2激酶的失活有关。
Blood. 2000 Oct 15;96(8):2746-54.

引用本文的文献

1
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities`.对ER+乳腺癌细胞中瑞博西尼、阿贝西利和哌柏西利耐药性的研究揭示了潜在的治疗机会。
Sci Rep. 2025 Aug 5;15(1):28579. doi: 10.1038/s41598-025-11052-4.
2
Circ_0001461 Regulates Colorectal Cancer Growth, Movement and Immune Escape Through miR-532-3p/AMOTL2.环状RNA_0001461通过miR-532-3p/血管生成素样蛋白2调节结直肠癌的生长、迁移和免疫逃逸。
Biochem Genet. 2025 Jun 26. doi: 10.1007/s10528-025-11162-8.
3
Fused pyrido[3,4-D]pyrimidine moiety with phthalazinone ring accelerate dual inhibition of PARP1 and CDK4 in triple-negative breast cancer: a hybrid design with computational investigation through molecular modeling and quantum mechanics.带有酞嗪酮环的稠合吡啶并[3,4-D]嘧啶部分加速对三阴性乳腺癌中PARP1和CDK4的双重抑制：通过分子建模和量子力学进行计算研究的混合设计
J Mol Model. 2025 Jun 4;31(7):181. doi: 10.1007/s00894-025-06393-w.
4
Novel -(4,5,6,7-tetrahydrobenzisoxazol-4-yl)amides as HSP90 inhibitors: design, synthesis and biological evaluation.新型-(4,5,6,7-四氢苯并异恶唑-4-基)酰胺作为HSP90抑制剂：设计、合成及生物学评价
RSC Med Chem. 2025 Mar 28. doi: 10.1039/d4md00904e.
5
Phytochemical Analysis and In Vivo Anticancer Effect of : Isolation and Characterization of a Promising Cytotoxic Diterpene.的植物化学分析及体内抗癌作用：一种有前景的细胞毒性二萜的分离与表征
Nutrients. 2025 Mar 27;17(7):1164. doi: 10.3390/nu17071164.
6
Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis.对FLT3抑制剂的耐药性涉及不同的分子机制，并减少新的DNA合成。
Biochem Biophys Rep. 2025 Jan 16;41:101894. doi: 10.1016/j.bbrep.2024.101894. eCollection 2025 Mar.
7
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.细胞周期蛋白依赖性蛋白激酶与生物学和疾病中的细胞周期调控
Signal Transduct Target Ther. 2025 Jan 13;10(1):11. doi: 10.1038/s41392-024-02080-z.
8
Identification of new tissue markers for the monitoring and standardization of penile cancer according to the degree of differentiation.根据分化程度鉴定用于阴茎癌监测和标准化的新组织标志物。
Histol Histopathol. 2025 Jul;40(7):1013-1039. doi: 10.14670/HH-18-846. Epub 2024 Nov 7.
9
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma.晚期透明细胞肾细胞癌的新兴创新治疗策略
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae276.
10
Evolution of the Cdk4/6-Cdkn2 system in invertebrates.无脊椎动物中 CDK4/6-Cdkn2 系统的进化。
Genes Cells. 2024 Nov;29(11):1037-1051. doi: 10.1111/gtc.13165. Epub 2024 Oct 8.

本文引用的文献

1
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.PD0332991 选择性抑制 CDK4/6 可使套细胞淋巴瘤患者产生肿瘤应答。
Blood. 2012 May 17;119(20):4597-607. doi: 10.1182/blood-2011-10-388298. Epub 2012 Mar 1.
2
Cdk1, but not Cdk2, is the sole Cdk that is essential and sufficient to drive resumption of meiosis in mouse oocytes.Cdk1，但不是 Cdk2，是唯一必需且充分的 Cdk，可驱动小鼠卵母细胞恢复减数分裂。
Hum Mol Genet. 2012 Jun 1;21(11):2476-84. doi: 10.1093/hmg/dds061. Epub 2012 Feb 24.
3
Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration.细胞周期蛋白依赖性激酶 1（Cdk1）对于细胞分裂和抑制 DNA 再复制是必需的，但对于肝脏再生则不是必需的。
Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3826-31. doi: 10.1073/pnas.1115201109. Epub 2012 Feb 21.
4
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.系统筛选 CDK4/6 底物将 FOXM1 磷酸化与癌细胞衰老抑制联系起来。
Cancer Cell. 2011 Nov 15;20(5):620-34. doi: 10.1016/j.ccr.2011.10.001.
5
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.在晚期癌症患者中，采用 21 天方案给药的口服细胞周期蛋白依赖性激酶 4/6 抑制剂 PD 0332991 的 I 期剂量递增试验。
Clin Cancer Res. 2012 Jan 15;18(2):568-76. doi: 10.1158/1078-0432.CCR-11-0509. Epub 2011 Nov 16.
6
Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.Cyclin D3 在 ErbB2 诱导的乳腺肿瘤起始和进展过程中补偿了 cyclin D1 的缺失。
Cancer Res. 2011 Dec 15;71(24):7513-24. doi: 10.1158/0008-5472.CAN-11-1783. Epub 2011 Oct 28.
7
Cyclin D as a therapeutic target in cancer.细胞周期蛋白 D 作为癌症治疗靶点。
Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi: 10.1038/nrc3090.
8
Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.肿瘤抑制因子 P16(INK4A)的调控机制及其与癌症的相关性。
Biochemistry. 2011 Jun 28;50(25):5566-82. doi: 10.1021/bi200642e. Epub 2011 Jun 6.
9
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).PD 0332991 的 I 期研究，一种周期蛋白依赖性激酶抑制剂，每 3 周给药一次（方案 2/1）。
Br J Cancer. 2011 Jun 7;104(12):1862-8. doi: 10.1038/bjc.2011.177. Epub 2011 May 24.
10
CDK6 kinase activity is required for thymocyte development.CDK6 激酶活性是胸腺细胞发育所必需的。
Blood. 2011 Jun 9;117(23):6120-31. doi: 10.1182/blood-2010-08-300517. Epub 2011 Apr 20.